Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel versus standard of care in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
NL-OMON60567Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mature B-cell lymphoma comparing Tisagenlecleucel treatment strategy with Standard-of-care treatment strategy (2 arms). Primary endpoint: Event-free survival by blinded independent review committee. Started Nov 2019; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON60567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60567.